Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 | Zendy

Eyal C. Attar | Zendy; Jeffrey L. Johnson | Zendy; Philip C. Amrein | Zendy; Gerard Lozanski | Zendy; Martha Wadleigh | Zendy; Daniel J. DeAngelo | Zendy; Jonathan E. Kolitz | Zendy; Bayard L. Powell | Zendy; Peter M. Voorhees | Zendy; Eunice S. Wang | Zendy; William Blum | Zendy; Richard M. Stone | Zendy; Guido Marcucci | Zendy; Clara D. Bloomfield | Zendy; Barry Kurt Moser | Zendy; Richard A. Larson | Zendy

Open Access

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Author(s) -

Eyal C. Attar,

Jeffrey L. Johnson,

Philip C. Amrein,

Gerard Lozanski,

Martha Wadleigh,

Daniel J. DeAngelo,

Jonathan E. Kolitz,

Bayard L. Powell,

Peter M. Voorhees,

Eunice S. Wang,

William Blum,

Richard M. Stone,

Guido Marcucci,

Clara D. Bloomfield,

Barry Kurt Moser,

Richard A. Larson

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.45.2177

Subject(s) - cytarabine , bortezomib , medicine , daunorubicin , myeloid leukemia , induction chemotherapy , gastroenterology , chemotherapy , leukemia , surgery , multiple myeloma

The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-dose cytarabine (Int-DAC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research